Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc.
Your view on ADXS
Overview
What the company does, where it operates, and who runs it.
About Ayala Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Kenneth A. Berlin
- Headquarters
- 9 Deer Park Drive, Monmouth Junction, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Kenneth A. Berlin
- Headquarters
- 9 Deer Park Drive, Monmouth Junction, NJ, US
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.